Celldex Therapeutics (CLDX) Amortization of Goodwill (2018)
Celldex Therapeutics' (CLDX) quarterly Amortization of Goodwill came in at -$24000.0 in Q2 2018, down 100.03% quarter-over-quarter from $91.0 million in Q1 2018.
Celldex Therapeutics (CLDX) Amortization of Goodwill (2018) Analysis & Trends
Celldex Therapeutics' Amortization of Goodwill history runs 1 years deep, the most recent figure standing at -$24000.0 for Q2 2018.
- On a quarterly basis, Amortization of Goodwill changed N/A year-over-year to -$24000.0 in Q2 2018; TTM through Dec 2018 was $91.0 million, a N/A change from a year earlier, with the FY2018 full-year figure at $91.0 million, changed N/A from the prior year.
- Amortization of Goodwill eased to -$24000.0 in Q2 2018 per CLDX's latest filing, from $91.0 million in the prior quarter.
- Across five years, Amortization of Goodwill topped out at $91.0 million in Q1 2018 and bottomed at -$24000.0 in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Celldex Therapeutics | 2.34 Bn | 2.34 Bn | -1.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2018 | -24,000.00 |
| Jun 30, 2018 | -24,000.00 |
| Mar 31, 2018 | 91.00 Mn |
| Mar 31, 2018 | 91.00 Mn |